nyuuzyou/wikis huggingface dataset:
All-trans retinoic acid (ATRA)

==General information==
Class/mechanism: Retinoid, induces maturation/differentiation of acute promyelocytic leukemia (APL) cells. Exact mechanism unknown.Tretinoin (Vesanoid) package insert Tretinoin (Vesanoid) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Acute myeloid leukemia, NPM1-mutated
*Acute promyelocytic leukemia
*Immune thrombocytopenia (ITP)
==Patient drug information==
*Tretinoin (Vesanoid) patient drug information (Chemocare)Tretinoin (Vesanoid) patient drug information (Chemocare)
*Tretinoin (Vesanoid) patient drug information (UpToDate)Tretinoin (Vesanoid) patient drug information (UpToDate)
==History of changes in FDA indication==
*1995-11-22: Initial FDA approval 
*2004-07-19: FDA approved for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARA gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline-based chemotherapy is contraindicated.
==History of changes in EMA indication==
*1994-03-31: EURD
==Also known as==
*Generic names: all-trans retinoic acid, ATRA, tretinoin
*Brand names: CA ATRA, Ves-ATRA, Vesanoid
==References==
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:Retinoids
Category:Acute myeloid leukemia medications
Category:Acute promyelocytic leukemia medications
Category:Immune thrombocytopenia medications
Category:FDA approved in 1995
Category:EMA approved in 1994
Category:WHO Essential Cancer Medicine
Allopurinol (Zyloprim)

==General information==
Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.
==History of changes in FDA indication==
* 1966-08-19: Initial approval
==Also known as==
*Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway
==References==
*FLORENCE: Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. Epub 2015 Jul 27. link to original article EuroPMC NCT01724528
Category:Drugs
Category:Intravenous medications
Category:Oral medications
Category:Xanthine oxidase inhibitors
Category:FDA approved in 1966
Category:WHO Essential Cancer Medicine
Alpelisib (Piqray)

==Mechanism of action==
From NCI Drug Dictionary: An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
==Diseases for which it is used==
*PIK3CA-mutated breast cancer
==Patient drug information==
*Alpelisib (Piqray) Package InsertAlpelisib (Piqray) Package Insert
==History of changes in FDA indication==
*2019-05-24: Approved in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. (Based on SOLAR-1)
==History of changes in EMA indication==
*2020-07-27: Initial authorization as Piqray in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
==History of changes in Health Canada indication==
*2020-03-11: Initial notice of compliance in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.
==Also known as==
*Code name: BYL-719
*Brand name: Piqray
==References==
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:Mutation-specific medications
Category:PI3K alpha inhibitors
Category:Breast cancer medications
Category:FDA approved in 2019
Category:EMA approved in 2020
Category:Health Canada approved in 2020
Alprazolam (Xanax)

Benzodiazepine with antiemetic properties, especially for anticipatory nausea. No known antineoplastic properties.
==Also known as==
*Brand name: Actazolam, Alam-PH, Alcalm, Alplax, Apazol, Azom, Azor, Copax, Frixitas, Onax, Pinix, Tafil, Tranax, Xanax, Xanor
Category:Drugs
Category:Oral medications
Category:Emesis prevention
Category:Benzodiazepine
Category:FDA approved in 1981
Altretamine (Hexalen)

==General information==
Class/mechanism: Alkylating-like, exact mechanism unknown—can form covalent adducts with tissue macromolecules including DNA.Altretamine (Hexalen) package insert Altretamine (Hexalen) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,or the prescribing information.
==Diseases for which it is used==
*Ovarian cancer
==Patient drug information==
*Altretamine (Hexalen) patient drug information (Chemocare)Altretamine (Hexalen) patient drug information (Chemocare)
*Altretamine (Hexalen) patient drug information (UpToDate)Altretamine (Hexalen) patient drug information (UpToDate)
==History of changes in FDA indication==
*1990-12-26: Initial FDA approval. Indicated for use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.
==History of changes in EMA indication==
*1979-01-22: EURD
==Also known as==
*Generic names: hexamethylmelamine, HMM
*Brand name: Hexalen, Hexastat
==References==
Category:Drugs
Category:Oral medications
Category:Alkylating agents
Category:Ovarian cancer medications
Category:FDA approved in 1990
Category:EMA approved in 1979
Alveolar soft part sarcoma

Back to Top
Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
Last updated on 2024-07-23:1 regimens on this page
3 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
=All lines of therapy=
==Atezolizumab monotherapy==
===Regimen variant #1, q3wk===
FDA-recommended dose
Study 	Dates of enrollment	Evidence
Chen et al. 2023 (Study ML39345)	2017-04 to 2022-07 	Phase 2 (RT)
====Immunotherapy====
*Atezolizumab (Tecentriq) by the following age-based criteria:
**18 years old or older: 1200 mg IV once on day 1
**Younger than 18 years old: 15 mg/kg (maximum dose of 1200 mg) IV once on day 1
21-day cycles
===Regimen variant #2, q2wk===
FDA-recommended dose
====Immunotherapy====
*Atezolizumab (Tecentriq) 840 mg IV once on day 1
14-day cycles
===Regimen variant #3, q4wk===
FDA-recommended dose
====Immunotherapy====
*Atezolizumab (Tecentriq) 1680 mg IV once on day 1
28-day cycles
===References===
#Study ML39345: Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, Van Tine BA, Conley AP, Read WL, Riedel RF, Burgess MA, Glod J, Davis EJ, Merriam P, Naqash AR, Fino KK, Miller BL, Wilsker DF, Begum A, Ferry-Galow KV, Deshpande HA, Schwartz GK, Ladle BH, Okuno SH, Beck JC, Chen JL, Takebe N, Fogli LK, Rosenberger CL, Parchment RE, Doroshow JH. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. N Engl J Med. 2023 Sep 7;389(10):911-921. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors EuroPMC NCT03141684
Category:Alveolar soft part sarcoma regimens
Category:Disease-specific pages
Category:Soft tissue sarcomas
Alvocidib (Flavopiridol)

==Mechanism of action==
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Acute myeloid leukemia===
# JHOC-J1101: Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep;100(9):1172-9. Epub 2015 May 28. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT01349972
==Also known as==
*Generic name: flavopiridol
*Code names: HMR-1275, L-868275
Category:Drugs
Category:Oral medications
Category:CDK inhibitors
Category:Acute myeloid leukemia medications (investigational)
Category:Investigational drugs
Amatuximab (MORAb-009)

==Mechanism of action==
From the NCI Drug Dictionary: A humanized IgG1 monoclonal antibody directed against human mesothelin with potential antineoplastic activity. Amatuximab binds to mesothelin, triggering an antibody dependent cellular cytotoxicity (ADCC)-mediated host immune response against mesothelin-expressing tumor cells, which may result in tumor cell lysis. Mesothelin, a 40kDa cell surface glycoprotein, is overexpressed in several human tumors, including mesothelioma and ovarian and pancreatic adenocarcinomas.
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Malignant pleural mesothelioma===
# Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. Epub 2014 Sep 17. link to PMC article EuroPMC
==Also known as==
*Code name: MORAb-009
Category:Drugs
Category:Intravenous medications
Category:Anti-mesothelin antibodies
Category:Malignant pleural mesothelioma medications (investigational)
Category:Investigational drugs
Amifostine (Ethyol)

==General information==
Class/mechanism: Prodrug of a free thiol metabolite, converted to the active form by alkaline phosphatase, that reduces the cumulative renal toxicity of cisplatin and oral toxicity of radiation by scavaging reactive metabolites and reactive oxygen species. Amifostine is thought to preferentially protect normal tissues because they have higher alkaline phosphatase activity, higher pH, and better vascularity.(Ethyol) package insert Amifostine (Ethyol) package insert (locally hosted backup)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,or the prescribing information.
==Patient drug information==
*Amifostine (Ethyol) patient drug information (Chemocare)Amifostine (Ethyol) patient drug information (Chemocare)
*Amifostine (Ethyol) patient drug information (UpToDate)Amifostine (Ethyol) patient drug information (UpToDate)
*Amifostine (Ethyol) Package Insert
==History of changes in FDA indication==
*1995-12-08: indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.
==Also known as==
*Brand names: Cytofos, Ethyol
==References==
Category:Drugs
Category:Intravenous medications
Category:Chemotherapy protective agents
Category:FDA approved in 1995
Aminocaproic acid (Amicar)

==General information==
Class/mechanism: Inhibits fibrinolysis by inhibiting plasminogen activators and via antiplasmin activity.Aminocaproic acid (Amicar) package insert Aminocaproic acid (Amicar) package insert (locally hosted backup) Aminocaproic acid tablets (Amicar) package insert (locally hosted backup)
Route: IV, PO
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape,or the prescribing information.
==Patient drug information==
*Aminocaproic acid (Amicar) patient drug information (UpToDate)Aminocaproic acid (Amicar) patient drug information (UpToDate)
==Also known as==
*Generic names: 6-aminohexanoic acid, epsilon aminocaproic acid, ε-aminocaproic acid, ε-Ahx
*Brand name: Amicar
==References==
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Hematology medications
Category:Hemostasis medications
Category:Fibrinolysis inhibitors
Category:FDA approved in 1964
Aminoglutethimide (Cytadren)

==General information==
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.Aminoglutethimide (Cytadren) package insert Aminoglutethimide (Cytadren) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it was used==
*Breast cancer
==Patient drug information==
*Aminoglutethimide (Cytadren) patient drug information (Chemocare)Aminoglutethimide (Cytadren) patient drug information (Chemocare)
==History of changes in FDA indication==
This medication does not have a specific cancer indication; it is indicated for Cushing Syndrome.
*1980-10-29: Initial approval
==Also known as==
*Brand names: Aminoblastin, Cytadren, Elipten, Orimentin, Orimeten, Orimetene, Rodazol
==References==
Category:Drugs
Category:Oral medications
Category:Steroid synthesis inhibitors
Category:Aromatase inhibitors, first generation
Category:Breast cancer medications (historic)
Category:FDA approved in 1980
Aminopterin

==General information==
Class/mechanism: Folate analog, antimetabolite, interferes with DNA synthesis. Discontinued due to concerns about toxicity, manufacturing difficulties, and rough equivalence to methotrexate. It remains under investigation for the non-neoplastic condition of psoriasis.
Route: IM
==Diseases for which it was used==
*B-cell acute lymphoblastic leukemia
==Also known as==
*Generic name: 4-aminopteroyl-glutamic acid
Category:Drugs
Category:Intramuscular medications
Category:Antimetabolites
Category:Antifolates
Category:B-cell acute lymphoblastic leukemia medications (historic)
Category:Investigational drugs
Category:Discontinued drugs
Amoxicillin

An antibiotic, sometimes used as a component of H. pylori eradication therapy.
==Also known as==
*Brand names: Amoxi, Amoxihexal, Amoxil, Biomox
Category:Drugs
Category:Oral medications
Category:Penicillin
Category:MALT lymphoma medications
Category:FDA approved in 1972
Category:WHO Essential Anti-infective Medicines
Amrubicin (Calsed)

==General information==
Class/mechanism: Synthetic third generation anthracycline and topoisomerase II inhibitor.Sumitomo Pharmaceuticals Co. press release about launch of amrubicin (Calsed) on 12/6/2002Dainippon Sumitomo Pharma submits an application for anticancer antibiotic amrubicin HCI (Brand name in Japan: CALSED®) in China, 9/5/2012
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Diseases for which it is used==
*Non-small cell lung cancer
*Small cell lung cancer
==Patient drug information==
No information available.
==History of changes in PMDA indication==
*2002-04-11: Initial approval for the treatment of small cell and non-small cell lung cancer.
==Also known as==
*Code name: SM-5887
*Generic names: AMR, amrubicin HCI
*Brand name: Calsed
==References==
Category:Drugs
Category:Intravenous medications
Category:Anthracyclines
Category:Topoisomerase II inhibitors
Category:Non-small cell lung cancer medications
Category:Small cell lung cancer medications
Category:PMDA approved drugs
Amsacrine (Amsidine)

==General information==
Class/mechanism: Synthetic acridine-derivate. Exact mechanism unclear; amsacrine binds to DNA by intercalation and external electrostatic binding, which inhibits DNA synthesis and causes DNA fragmentation.Amsacrine (Amsidine) package insert Amsacrine (Amsidine) package insert (locally hosted backup)
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.
==Patient drug information==
*Amsacrine (Amsidine) patient drug information (UpToDate)Amsacrine (Amsidine) patient drug information (UpToDate)
==Diseases for which it is used==
*Acute myeloid leukemia, pediatric
==History of changes in EMA indication==
*1982-04-23: EURD
==Also known as==
*Code names: CI-880, SN-11841
*Generic names: acridinyl anisidide, AMSA, Cain's acridine, m-AMSA
*Brand names: Amekrin, Amsa P-D, Amsidine, Amsidyl, Lamasine
==References==
Category:Drugs
Category:Intravenous medications
Category:Vesicant
Category:Human DNA synthesis inhibitors
Category:Topoisomerase II inhibitors
Category:Acute myeloid leukemia medications (historic)
Category:EMA approved in 1982
Category:Health Canada approved drugs
Anagrelide (Agrylin)

==General information==
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.Anagrelide (Agrylin) package insert Anagrelide (Agrylin) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
*Example of usage: Anagrelide (Agrylin) 0.5 mg PO four times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, or the prescribing information.
==Diseases for which it is used==
*Essential thrombocythemia
*Polycythemia vera
==Patient drug information==
*Anagrelide (Agrylin) patient drug information (Chemocare)Anagrelide (Agrylin) patient drug information (Chemocare)
*Anagrelide (Agrylin) patient drug information (UpToDate)Anagrelide (Agrylin) patient drug information (UpToDate)
==History of changes in EMA indication==
*2004-11-15: Initial approval as Xagrid for the reduction of elevated platelet counts in at-risk essential-thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient is defined by one or more of the following features: 60 years of age or more; a platelet count 1000 x 109/l or more; or a history of thrombohaemorrhagic events.
==History of changes in FDA indication==
*1997-03-14: Initial approval
*1998-12-16 (oldest label available online): Approved for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic event.
==History of changes in PMDA indication==
*2014-09-26: Initial approval for the treatment of essential thrombocythemia.
==Also known as==
*Brand names: Agrylin, Xagrid
==References==
Category:Drugs
Category:Oral medications
Category:Hematology medications
Category:Phosphodiesterase inhibitors
Category:Essential thrombocythemia medications
Category:Polycythemia vera medications
Category:FDA approved in 1997
Category:EMA approved in 2004
Category:PMDA approved in 2014